William Petty to Carcinoma, Non-Small-Cell Lung
This is a "connection" page, showing publications William Petty has written about Carcinoma, Non-Small-Cell Lung.
Connection Strength
1.143
-
Petty WJ, Laudadio J, Brautnick L, Lovato J, Dotson T, Streer NP, Weaver KE, Miller AA. Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer. Int J Oncol. 2013 Dec; 43(6):2057-63.
Score: 0.441
-
Ruiz J, Miller AA, Tooze JA, Crane S, Petty WJ, Gajra A, Klepin HD. Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age. J Geriatr Oncol. 2019 01; 10(1):48-54.
Score: 0.153
-
Duggan KT, Hildebrand Duffus S, D'Agostino RB, Petty WJ, Streer NP, Stephenson RC. The Impact of Hospice Services in the Care of Patients with Advanced Stage Nonsmall Cell Lung Cancer. J Palliat Med. 2017 01; 20(1):29-34.
Score: 0.135
-
Kilburn JM, Lester SC, Lucas JT, Soike MH, Blackstock AW, Kearns WT, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ. Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer. J Thorac Oncol. 2014 Apr; 9(4):572-6.
Score: 0.114
-
Kilburn JM, Kuremsky JG, Blackstock AW, Munley MT, Kearns WT, Hinson WH, Lovato JF, Miller AA, Petty WJ, Urbanic JJ. Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment. Radiother Oncol. 2014 Mar; 110(3):505-10.
Score: 0.112
-
Socinski MA, Stinchcombe TE, Moore DT, Gettinger SN, Decker RH, Petty WJ, Blackstock AW, Schwartz G, Lankford S, Khandani A, Morris DE. Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial. J Clin Oncol. 2012 Nov 10; 30(32):3953-9.
Score: 0.103
-
Center B, Petty WJ, Ayala D, Hinson WH, Lovato J, Capellari J, Oaks T, Miller AA, Blackstock AW. A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer. J Thorac Oncol. 2010 Jan; 5(1):69-74.
Score: 0.085